Key result
Intensive BP control reduces MACE in hypertension regardless of baseline frailty status.
Why the study?
Evidence regarding the benefits and harms of intensive blood pressure control in patients with higher degrees of frailty was limited.
Does intensive blood pressure-lowering treatment targeting systolic BP <120 mm Hg reduce MACE and is it safe across different frailty statuses in hypertensive patients with high cardiovascular risk?
RCT
Does intensive blood pressure-lowering treatment targeting systolic BP <120 mm Hg reduce MACE and is it safe across different frailty statuses in hypertensive patients with high cardiovascular risk?
Intensive blood pressure control targeting systolic BP <120 mm Hg provides consistent cardiovascular benefits without increased safety risks in high-risk hypertensive patients, regardless of their baseline frailty status.
Answers are grounded in this paper and cite their sources.
Intensive BP control targeting <120 mm Hg may benefit high-risk hypertensives irrespective of frailty; hypothesis-generating post hoc analysis warrants prospective confirmation before practice change.
BACKGROUND: Evidence regarding the benefits and harms of intensive blood pressure (BP) control in patients with higher degrees of frailty is limited. OBJECTIVES: We aimed to characterize the benefit-harm profile of intensive BP control by frailty status in the ESPRIT trial. METHODS: In this post hoc analysis of the ESPRIT trial, we categorized participants into nonfrail, moderately frail, and severely frail according to their baseline frailty index (FI), which was calculated by the Rockwood cumulative deficit approach. We examined heterogeneity in the effect of intensive BP-lowering treatment on major adverse cardiovascular events (MACE) (a composite of myocardial infarction, hospitalization for heart failure, stroke, or death from cardiovascular diseases), all-cause death, and safety outcomes (kidney outcomes, and other serious adverse events of special interest [hypotension, syncope, electrolyte abnormality, injurious fall, or acute kidney injury]). Effects on all-cause death showed a similar pattern. Greater absolute risk reductions in MACE, cardiovascular death, and all-cause death were observed with increasing frailty, but the interactions were not significant. The effects of intensive treatment were also consistent across the spectrum of continuous FI. None of the safety outcomes differed by frailty status. CONCLUSIONS: Hypertensive patients with high cardiovascular risk benefit from the treatment strategy of targeting systolic BP <120 mm Hg, regardless of their frailty status. In addition, the effects of intensive treatment on experiencing adverse events did not differ by frailty status. (The Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs [ESPRIT]; NCT04030234).
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) conducted an RCT in Hypertension. Intensive blood pressure control was evaluated on Major adverse cardiovascular events (MACE) (composite of myocardial infarction, hospitalization for heart failure, stroke, or death from cardiovascular diseases).
Synapse has enriched 10 related papers. Consider them for comparative context: